GBG
Government
Bioscience
Grants

Updated Monthly

May 10, 2023

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:

G2G Consulting

Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com
www.G2Gconsulting.com
@G2Gconsulting

GBG Report

Updated Monthly

May 10, 2023

https://www.g2gconsulting.com/gbg-reporting-service/

TABLE OF CONTENTS

New Opportunities

Recurring Opportunities

May 19, 2023 – Join us for G2G's Monthly Non-Dilutive Funding: GBG Reporting Service Webinar at 10-10:30am EST (FREE and open to all) then from 10:30-11am EST (premium service and private consultation for G2G and GBG customers).

MTEC is hosting their 8th Annual Meeting at the Richmond Marriott on May 23-24. MTEC members can connect directly with military/government sponsors, and learn about MTEC initiatives directly from leadership. A virtual option is available.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ALZHEIMER'S DISEASE (3)		
1.	Development and Validation of Models for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) (NIH/NINDS/NIA) PAR-23-154	This NOFO supports the development and validation of clinically- and pathophysiologically-relevant models of ADRD. These models need to be innovative and address a gap in the currently available models. Models could include in vivo models, ex vivo models, human induced Pluripotent Stem Cells (iPSCs), organoids, tissue-on-chip, or other in vitro models. Rigorous validation is required. This includes internal, face, construct, and predictive validation. https://grants.nih.gov/grants/guide/pa-files/PAR-23-154.html	Up to $600,000 per year, for up to 5 years	Letter of intent: 5/20/23 Proposal: 6/20/23
2.	Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 CT Optional) (NIH/NIA) PAR-23-179	The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. https://grants.nih.gov/grants/guide/pa-files/PAR-23-179.html	Up to $100,000 per year, for up to 2 years	Proposal: 7/19/23
3.	Center without Walls for PET Ligand Development for Alzheimer's disease-related dementias (ADRDs) (U19 - Clinical Trial Optional) (NIH/NINDS/NIA) RFA-NS-24-011	This NOFO seeks multidisciplinary teams dedicated to the development of PET radioligands capable of labeling pathology associated with ADRDs. Each CWOW must propose to fully develop at least two ADRD-related PET ligands by conducting all necessary in vitro and in vivo studies from medicinal chemistry through and including IND-approved human research in the relevant patient populations. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-011.html	Up to $3.75 million per year, for up to 5 years	Proposal: 9/26/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AUTISM (1)		
4.	FY23 Autism Research Program (ARP) (DoD/CDMRP) HT9425-23-ARP-DA	The FY23 ARP Discovery Award supports innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications in autism research. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation regarding an important question for autism research and/or the ASD community. https://cdmrp.health.mil/funding/arp	Up to $200,000, for up to 2 years	Pre-Application: 6/29/23 Proposal: 7/20/23
		AUTOIMMUNE DISEASES (1)		
5.	NOSI: EXposome in Autoimmune Disease Collaborating Teams PLANning Awards (EXACT-PLAN) (Clinical Trials Not Allowed) (NIH) NOT-OD-23-112	This NOSI invites applications for exploratory, early, and conceptual stage research projects aimed at the design, development, and implementation of a future national, interdisciplinary, collaborative, team science research network that will advance the study of the exposome in autoimmune diseases. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-23-112.html	Up to $275,000, for up to 2 years	Proposal: 6/16/23
		BIOENGINEERING (3)		
6.	Tellus (DoD/DARPA) HR001123S0027	The goal of the DARPA Tellus program is to develop the Methodology to program microbial sense-and-respond devices to reliably detect a variety of chemical and physical stimuli, process this information and generate measurable output signals in DoD-relevant environments. Tellus will assess the feasibility of utilizing microbial devices for environmental monitoring. https://sam.gov/opp/73a0c18d357c47b1af9724a675f22c1f/view	Dependent upon proposal and available funding	Abstract: 5/18/23 Proposal: 7/6/23
7.	Pre-Announcement: National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional) (NIH/NIBIB) NOT-EB-23-007	This NOFO encourages grant applications for NCBIB. NCBIB are national resource centers for conducting research and development on new technologies that are driven by the needs of basic, translational, and/or clinical researchers. NCBIB also make their technologies available to other investigators, train members of the research community in the use of the technologies and disseminate the technologies broadly. https://grants.nih.gov/grants/guide/notice-files/NOT-EB-23-007.html	Dependent upon proposal and award mechanism	Estimated post date: 8/1/23 Estimated proposal date: 9/25/23
8.	Biophotonics (NSF) PD 23-7236	The goal of the Biophotonics program is to explore the research frontiers in photonics principles, engineering and technology that are relevant for critical problems in fields of medicine, biology and biotechnology. Low cost and minimally invasive medical diagnostics and therapies are key motivating application goals. https://new.nsf.gov/funding/opportunities/biophotonics-2	Dependent upon proposal and award mechanism	Full proposal accepted anytime

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BONE MARROW FAILURE (2)		
9.	FY23 Bone Marrow Failure Research Program (BMFRP) (DoD/CDMRP) HT9425-23-BMFRP-IDA HT9425-23-BMFRP-IIRA	The objective of the FY23 BMFRP is to fund research in the areas of congenital or acquired BMF. Applications to each of the two awards must address at least one of these two Focus Areas: Understand the causes and progression of BMF diseases; Find effective BMF treatments and cures. https://cdmrp.health.mil/funding/bmfrp	Up to $850,000, for up to 3 years Dependent upon proposal and award mechanism	Pre-Application: 6/21/23 Proposal: 9/20/23
		CANCER (35)		
10.	FY23 Breast Cancer Research Program (BCRP) (DoD/CDMRP) HT9425-23-BCRP-BTA12-2 HT9425-23-BCRP-BTA3-2 HT9425-23-BCRP-BTA4-2 HT9425-23-BCRP-CREA2 HT9425-23-BCRP-EOHS-2 HT9425-23-BCRP-INNOV-2 HT9425-23-BCRP-TBCCDA-2 HT9425-23-BCRP-TBCCA-2	A second round of BCRP awards has been announced. The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. Considering the current breast cancer landscape and the BCRP's mission to end breast cancer, the BCRP seeks applications that address overarching challenges. https://cdmrp.health.mil/funding/bcrp	Up to $25 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 6/6/23 Proposal: 6/22/23 (CREA) Pre-Application: 6/29/23 Invited proposal: 9/26/23 (TBCCA/BTA3/ BTA4/INNOV) Pre-Application: 7/25/23 Proposal: 8/8/23 (BTA12/EOHS/ TBCCDA)
11.	FY23 Lung Cancer Research Program (DoD/CDMRP) HT9425-23-LCRP-PCOSA	A new award mechanism was announced: Patient-Centered Outcomes and Survivorship Award. Applications submitted to the FY23 LCRP must address one or more of the following Areas of Emphasis: Biology and Etiology; Prevention; Detection, Diagnosis, and Surveillance; Treatment and Prognosis; Health Outcomes and Survivorship; Disparities. https://cdmrp.health.mil/funding/lcrp	Up to $650,000, for up to 3 years	Pre-Application: 7/20/23 Proposal: 8/14/23
12.	FY23 Pancreatic Cancer Research Program (PCARP) (DoD/CDMRP) HT9425-23-PCARP-IDA HT9425-23-PCARP-TRPA	Three FY23 PCARP awards are open: Idea Development Award, Translational Research Partnership Award, and the new Focused Pilot Award. Applications must address one or more of the Focus Areas. https://cdmrp.health.mil/funding/pcarp	Up to $750,000, for up to 3 years Dependent upon award mechanism	Pre-Application: 7/10/23 Proposal: 10/5/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
13.	FY23 Prostate Cancer Research Program (PCRP) (DoD/CDMRP) HT9425-23-PCRP-DSA HT9425-23-PCRP-HDRA HT9425-23-PCRP-TSA	The PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. All applications must address one or more of the FY23 PCRP Overarching Challenges. Four awards were previously published; the remaining three (Data Science Award, Health Disparity Research Award, and Translational Science Award) are now open. https://cdmrp.health.mil/funding/pcrp	Up to $1 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 8/3/23 Proposal: 8/24/23
14.	FY23 Rare Cancers Research Program (RCRP) (DoD/CDMRP) HT9425-23-RCRP-CA HT9425-23-RCRP-IDA HT9425-23-RCRP-RCDA	Applications submitted to the FY23 RCRP Concept Award and Idea Development Award must address one or more of the following Focus Areas: Biology and Etiology; Research Model; Therapy. Applications submitted to the FY23 RCRP Resource and Community Development Award must address the Platform Development Focus Area. https://cdmrp.health.mil/funding/rcrp	Up to $800,000, for up to 4 years Dependent upon award mechanism	Pre-Application: 6/26/23 Proposal: 9/29/23 (IDA/RCDA) Pre-Application: 7/14/23 Proposal: 8/25/23 (CA)
15.	NOSI: RNA Modifications in Cancer Biology (NIH/NCI) NOT-CA-23-060	The NCI intends to stimulate research on the role of RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert a substantial impact on gene expression and function, there is a lack of mechanistic insights into the dynamic regulation of RNA modifications and their de-regulation as drivers of cancer formation. A better understanding of the extent, diversity, and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underly cancer formation and the cancer phenotype. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-060.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/26
16.	Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) (NIH/NCI) PAR-23-155	This NOFO solicits mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. https://grants.nih.gov/grants/guide/pa-files/PAR-23-155.html	Dependent upon proposal, for up to 5 years	Proposal: 6/15/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
17.	Cancer Immunoprevention Network (CIP-Net) Research Projects (UG3/UH3 Clinical Trials Not Allowed) (NIH/NCI) RFA-CA-23-029	NCI intends to establish a Cancer Immunoprevention Network (CIP-Net) to support a deeper understanding of basic mechanisms of immunoprevention, discover novel immunoprevention strategies, preclinical development and testing of interventions, and foster a community of cancer immunoprevention researchers. The UG3/UH3 research projects will enable de novo discovery of immune pathways, targets, immunoprevention mechanisms, or investigate the efficacy and potential side effects of new vaccines or immunomodulatory agents. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-029.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 6/3/23 Proposal: 7/3/23
18.	Integrating Health Disparities into Immuno-Oncology (HDIO) (P20 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-23-038	This FOA is expected to enable complementary, multi-disciplinary research teams to address interdisciplinary research to integrate cancer health disparities into immuno-oncology research. It is anticipated these feasibility or pilot studies will support the exploration of novel or high-risk research hypotheses. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-038.html	Up to $250,000 per year, for up to 2 years	Letter of intent: 5/30/23 Proposal: 6/30/23
19.	Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) (NIH/NCI) RFA-CA-24-005	This NOFO solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-005.html	Up to $475,000 per year, for up to 5 years	Letter of intent: 9/13/23 Proposal: 10/13/23
20.	Pre-Announcement: FY23 Kidney Cancer Research Program (RTRP) (DoD/CDMRP)	Applications to the eight anticipated awards must address one or more Focus Areas. Awards are: Academy of Kidney Cancer Scholars; Clinical Trial Award; Concept Award; Idea Development Award; Clinical Consortium Award; Nurse-Initiated Research Award; Postdoctoral and Clinical Fellowship Award; Translational Research Partnership Award. https://cdmrp.health.mil/pubs/press/2023/23kcrppreann	Up to $6 million, for up to 4 years Dependent upon award mechanism	TBD
		CARDIOVASCULAR AND PULMONARY HEALTH (2)		
21.	Just Breathe – An ARDS Therapeutics Pitch Event (HHS/BARDA)	In this trial, BARDA will evaluate the safety and efficacy of novel threat-agnostic and host-directed therapeutics that could address ARDS caused by known or unknown health security threats such as pandemic influenza, COVID-19, other emerging infectious diseases, and chemical, biological, radiological, and nuclear (CBRN) incidents. https://www.medicalcountermeasures.gov/federal-initiatives/public-meetings/just-breathe/	Phase 2 ARDS platform clinical trial	Initial submission: 6/2/23 Final submission: 6/30/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH		
22.	Health System Strategies to Address Disparities in Hypertension Management & Control -- Cycle 2 2023 (PCORI)	This PFA solicits applications that respond to the following question: What is the comparative effectiveness of health system strategies to improve hypertension control for populations experiencing disparities in hypertension control and associated health outcomes? Studies that provide knowledge about an intervention's impact on multiple subgroups are strongly encouraged. https://www.pcori.org/funding-opportunities/announcement/health-system-strategies-address-disparities-hypertension-management-control-cycle-2-2023	Up to $15 million, for up to 5 years	Letter of intent: 5/31/23 Proposal: 8/29/23
		CHRONIC PAIN & PAIN MANAGEMENT (2)		
23.	HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional) (NIH) RFA-NS-23-028	This NOFO is designed to support interdisciplinary research teams of multiple PDs/PIs to investigate the mechanism of action of pain relief by medical devices with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-028.html	Up to $1.5 million per year, for up to 5 years	Letter of intent: 5/13/23 Proposal: 6/13/23
24.	Comparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention -- Cycle 2 2023 (PCORI)	This FOA solicits applications that respond to the following question: What is the comparative effectiveness of novel pharmacologic and/or evidence-based nonpharmacologic treatments for the prevention of migraine? PCORI is particularly interested in studies that compare emerging pharmacological options such as CGRP antagonists to standard prophylactic therapy or to each other. https://www.pcori.org/funding-opportunities/announcement/comparative-effectiveness-novel-pharmacologic-and-evidence-based-nonpharmacologic-treatments-migraine-prevention-cycle-2-2023	Up to $10 million, for up to 10 years	Letter of intent: 5/31/23 Proposal: 8/29/23
		COGNITIVE AND BRAIN HEALTH (13)		
25.	NOSI: NIMH Planning Grants for Natural History Studies of Rare Genetic Neurodevelopmental Disorders (NIH/NIMH) NOT-MH-23-235	This NOSI encourages planning grants to conduct retrospective natural history studies of rare genetic neurodevelopmental disorders. These studies are intended to enable future prospective natural history studies to further define the trajectory of psychiatric symptoms, clinical functional measures and biomarkers, and to address unmet needs for therapeutic development relevant to psychiatry. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-235.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
26.	NOSI: Pre-Clinical Research on Gene Therapies for Rare Genetic Neurodevelopmental Disorders (NIH/NIMH) NOT-MH-23-236	NIMH is encouraging research to establish, optimize, and evaluate technologies and assays needed for the clinical development of somatic cell gene therapies to treat rare neurodevelopmental disorders with prominent cognitive, social and/or affective impairment. Applicants may utilize novel genome targeting technologies and/or brain access and delivery systems. A range of cell-based assays, small animal or large animal assays may be appropriate to pre-clinically test the utility of the candidate therapeutic approaches. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-236.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/26
27.	NIH Blueprint for Neuroscience Research: Tools and Technologies to Explore Nervous System Biomolecular Condensates (R21 Clinical Trial Not Allowed) (NIH) RFA-DA-24-039	This NOFO supports the development of innovative tools and/or technologies to monitor or manipulate biomolecular condensates (BMCs) in vivo and enable investigators to adopt these tools to answer outstanding questions in basic neuroscience. This research will transform our understanding of the mechanistic role of BMCs in human nervous system health and disease and may serve as the foundation for the development of novel BMC-based therapeutics. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-039.html	Up to $275,000, for up to 2 years	Letter of intent: 10/14/23 Proposal: 11/14/23
28.	BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) (NIH) RFA-MH-23-290	The purpose of this Initiative is to encourage research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-290.html	Dependent upon proposal, for up to 3 years	Proposal: 6/7/23
29.	BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional) (NIH) RFA-MH-23-295	This NOFO encourages applications that will develop and validate novel tools to facilitate the detailed analysis and manipulation of complex circuits in large brains. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-295.html	Dependent upon proposal, for up to 5 years	Proposal: 6/7/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
30.	BRAIN Initiative: Targeted BRAIN Circuits – TargetedBCPP and TargetedBCP (R34/R01 Clinical Trials Not Allowed) (NIH) RFA-NS-23-023 (R34) RFA-NS-23-024 (R01)	These NOFOs support adventurous projects that can realize a potentially transformative outcome within 5 years, as well as exploratory research that will support, enable, or lay the groundwork for a subsequent project. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-023.html (R34) https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-024.html (R01)	Up to $225,000 per year, for up to 2 years (R34) Dependent upon proposal, for up to 5 years (R01)	Letter of intent: 5/30/23 Proposal: 6/30/23
31.	BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP (U01 Clinical Trials Optional) (NIH) RFA-NS-23-025	This NOFO is designed to support teams of three or more (up to six) PDs/PIs that seek to cross boundaries of interdisciplinary collaboration to elucidate the contributions of dynamic circuit activity to a specific behavioral or neural system. Applications are encouraged to propose adventurous and challenging goals that can only be tackled by a synergistic team-based approach and have the potential to be transformative and/or to enable significant advances. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-025.html	Dependent upon proposal, for 3 years	Letter of intent: 5/15/23 Proposal: 6/15/23
32.	NINDS Sustainable Transformation of Institutional Research Rigor (STIRR) Program (RC2 - Clinical Trial Not Allowed) (NIH/NINDS) RFA-NS-24-020	This NOFO aims to support the establishment of programs to enhance research rigor and transparency practices within academic and research institutions to promote a culture of high-quality neuroscience research. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-020.html	Dependent upon proposal, for up to 3 years	Letter of intent: 9/17/23 Proposal: 10/17/23
		CORONAVIRUS (2)		
33.	Emergency Award: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21) and RADx-®UP D&I Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations(R01) (NIH) RFA-OD-23-050 (R21) RFA-OD-23-051 (R01)	These NOFOs will support analyses of existing RADx-UP data by proposing novel questions related to SARS-CoV-2 testing and health disparities and to support dissemination and implementation (D&I) research focused on increasing access to and uptake of coronavirus disease 2019 (COVID-19) testing interventions – with the goal of reducing COVID-19 disparities and promoting health equity among underserved and vulnerable populations. https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-050.html (R21) https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-051.html (R01)	Up to $275,000, for up to 2 years (R21) Up to $1.8 million, for up to 3 years (R01)	Letter of intent: 6/2/23 Proposal: 7/3/23 (R21) Letter of intent: 6/9/23 Proposal: 7/10/23 (R01)

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DUCHENNE MUSCULAR DYSTROPHY (2)		
34.	Pre-Announcement: FY23 Duchenne Muscular Dystrophy Research Program (DMDRP) (DoD/CDMRP)	All applications for the FY23 DMDRP Idea Development Award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that focus on primary pathology of DMD. Applications for the FY23 DMDRP Translational Research Award must address at least one Focus Area. https://cdmrp.health.mil/pubs/press/2023/23dmdrppreann	Up to $1.35 million, for up to 3 years Dependent on award mechanism	TBD
		ENDOCRINE AND METABOLIC DISEASES (3)		
35.	NOSI: Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) (NIH/NIDDK) NOT-DK-23-013	This NOSI provides funding for developing novel tools and technologies that enable new lines of scientific inquiry and/or treatment, prevention, or diagnosis of Polycystic Kidney Disease (PKD). https://grants.nih.gov/grants/guide/notice-files/NOT-DK-23-013.html	Up to $275,000, for up to 2 years	Proposal: 6/16/23
36.	Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 CT Not Allowed) (NIH/NIDDK) PAR-23-119	This FOA aims to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases. https://grants.nih.gov/grants/guide/pa-files/PAR-23-119.html	Up to $275,000, for up to 2 years	Proposal: 6/16/23
37.	Human Liver Tissue and Hepatocytes Resource-Related Research Project (R24 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-23-012	This NOFO will support a Human Liver Tissue and Hepatocytes Research Resource (HLTHRR) program to enable the continued availability of human liver tissue and hepatocytes to biomedical researchers. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-012.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 7/30/23 Proposal: 8/30/23
		GENERAL MEDICAL SCIENCES (1)		
38.	Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (ESI) (R35 - Clinical Trial Optional) (NIH/NIGMS) PAR-23-145	This NOFO provides support for a program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. https://grants.nih.gov/grants/guide/pa-files/PAR-23-145.html	Up to $250,000 per year, for up to 5 years	Proposal: 10/3/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GENOMICS (1)		
39.	Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional) (NIH/NHGRI/NIMH) PAR-23-098	Each CEGS award supports a multi-investigator, interdisciplinary team to develop integrated, transformative genomic approaches to address a biomedical problem. A CEGS project will address a critical issue in genomic science, genomic medicine, or computational genomics, proposing a highly innovative solution that would be a major advance https://grants.nih.gov/grants/guide/pa-files/PAR-23-098.html	Up to $1.5 million per year, for up to 5 years	Letter of intent: 5/11/23 Proposal: 6/23/23
		HEALTH IT (3)		
40.	NOSI: Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging (NIH/NIA) NOT-AG-23-020	This NOSI encourages the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan, (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-23-020.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/24
41.	Data Integration and Statistical Analysis Methods (DISAM) (U01 Clinical Trial Not Allowed) (NIH) RFA-HG-23-005	This NOFO solicits applications to develop innovative and generalizable statistical and computational methods for analysis of data from the human Developmental Genotype-Expression (dGTEx) and non-human primate (NHP dGTEx) projects. Methods that assess the influence of genetic variation on development, compare gene expression and regulation across tissues and time points, or leverage comparative genomics to understand developmental and evolutionary processes and integrate with existing tissue and cell atlas efforts are strongly encouraged. https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-005.html	Up to $400,000, for up to 3 years	Letter of intent: 10/20/23 Proposal: 11/20/23
42.	BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) (NIH) RFA-MH-23-270	This NOFO solicits applications to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative or to enhance our understanding of the brain. The tools supported under this NOFO will make use of relevant data standards and will be built so that they can be integrated into the data repositories. The tools must be user-friendly in accessing and analyzing data from appropriate data archives, and should analyze/visualize data without requiring users to download data. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-270.html	Dependent upon proposal, for up to 3 years	Proposal: 6/9/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS (3)		
43.	Pre-Announcement: PATC³H-IN Implementation Science Coordinating Center (UM2 Clinical Trial Optional) (NIH/NICHD) NOT-HD-23-009	PATC3H-IN will establish a network of investigators with multidisciplinary expertise on the youth-specific HIV prevention and/or HIV care continuum and in IS research, whose mission will be to evaluate promising prevention innovations contextually and developmentally tailored for HIV uninfected at-risk youth, and treatment and care interventions for youth living with HIV which have demonstrated efficacy and/or effectiveness in adolescent or adult populations and to translate them into public health practices. https://grants.nih.gov/grants/guide/notice-files/NOT-HD-23-009.html	TBD	Estimated post date: 7/28/23 Estimated proposal date: 12/6/23
44.	Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed) (NIH/NIAID) PAR-23-169	This NOFO supports high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. https://grants.nih.gov/grants/guide/pa-files/PAR-23-169.html	Up to $350,000 per year, for up to 4 years	Proposal: 8/2/23
45.	Synthetic Nucleic Acid Platforms for HIV-1 (SNAPH): (R61/R33 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-23-026	This NOFO aims to advance synthetic nucleic acid platforms for the rapid development and iterative testing of active and passive immunization strategies for HIV prevention, treatment, and cure. This NOFO will use a milestone-driven, biphasic award mechanism. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-026.html	Up to $500,000 per year, for up to 3 years (R61) Up to $750,000 per year, for up to 2 years (R33)	Letter of intent: 7/2/23 Proposal: 8/2/23
		IMMUNOLOGY & INFECTIOUS DISEASE (4)		
46.	Pre-Announcement: Innovations in Functional B Cell Epitope Discovery (NIH/NIAID) BAA-NIAID-75N93023R00002	This program will support discovery and validation of novel human B cell epitopes that elicit antibodies associated with: antibody-mediated protection or pathogenesis in the context of infectious agents or vaccines against them including pathogens with pandemic potential; host B cell epitopes associated with autoimmune diseases; B cell epitopes associated with allergens; and HLA epitopes associated with cell/organ/tissue transplant rejection or tolerance. https://sam.gov/opp/ad02768b576346718f8bacd63d2cb5ea/view	Dependent upon proposal and contract	Estimated post date: 5/23/23
47.	Emerging Infections Program (CDC/NCEZID) CDC-RFA-CK24-2401	This NOFO sustains and enhances the multi-site EIP network which provides high quality scientific information to monitor emerging infectious diseases in the U.S., evaluate public health interventions, and inform public health policy. Activities of the EIP network include infrastructure and data modernization to support: (1) active surveillance; (2) applied public health epidemiologic and laboratory activities; (3) implementation and evaluation of pilot prevention/intervention projects; and (4) rapid and flexible response to public health emergencies and newly emerging issues for infectious diseases. https://www.grants.gov/web/grants/view-opportunity.html?oppId=345775	Dependent upon proposal and award mechanism	Proposal: 6/20/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
48.	Pre-Announcement: Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional) (NIH/NCI) NOT-CA-23-067	This NOFO will solicit applications to expand the research scope and leverage the gains made through the "Investigation of the Transmission of KSHV" to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-067.html	Up to $500,000 per year	Estimated post date: 10/2/23 Estimated proposal date: 12/14/23
49.	International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-23-023	This FOA supports applications for high-priority, regionally relevant infectious diseases research by international investigators in resource-constrained countries. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-023.html	Up to $125,000 per year, for up to 5 years	Letter of intent: 7/2/23 Proposal: 8/2/23
		JOINT WARFIGHTER MEDICAL (1)		
50.	FY23 Joint Warfighter Medical Research Program (JWMRP) (DoD/CDMRP) HT9425-23-S-JWMRP-MMRDA	The FY23 JWMRP aims to augment and accelerate progress toward critical DOD medical capability gaps and requirements through the continuation of research and development initiatives that were previously supported by DOD core and/or DOD congressionally directed funding and that are close to achieving their objectives and yielding a benefit to military medicine. Applications submitted to the FY23 JWMRP must address at least one of the following Focus Areas: Endemic and Emerging Disease Threats; Operational Medicine and Readiness; Environmental Medicine; Combat Casualty Care. Applicants must have already received DOD core or DOD congressionally directed prior year funding for the same research and/or development project being proposed for logical continuation under this funding opportunity. https://cdmrp.health.mil/funding/jwmrp	Up to $3.5 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 6/15/23 Proposal: 9/7/23
		LUPUS (3)		
51.	FY23 Lupus Research Program (LRP) (DoD/CDMRP) HT9425-23-LRP-IA HT9425-23-LRP-IPA HT9425-23-LRP-TVA	Applications submitted to the three awards of the FY23 LRP must address one or more of the Focus Areasspecific to each award. https://cdmrp.health.mil/funding/lrp	Up to $2.5 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 7/20/23 Proposal: 8/10/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MATERNAL AND PEDIATRIC HEALTH (2)		
52.	Pre-Announcement: Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors – Biostatistics Research Center and Clinical Centers (U01 Clinical Trial Not Allowed) (NIH/NIDDK) NOT-DK-23-017 NOT-DK-23-018	NIDDK will solicit applications for a Biostatistics Research Center (BRC) and Clinical Centers to participate in a clinical consortium to better understand the neurocognitive impact of new onset type 1 diabetes (T1D) in pre-pubertal children. Clinical Centers will establish a diverse cohort of pre-pubertal children newly diagnosed with T1D and will longitudinally evaluate disease-related perturbations in neurocognitive function, as well as identify potential clinical, developmental, and/or environmental factors associated with neurocognitive function in T1D. https://grants.nih.gov/grants/guide/notice-files/NOT-DK-23-017.html (BRC) https://grants.nih.gov/grants/guide/notice-files/NOT-DK-23-018.html (CC)	Up to $1.2 million for one year, and $2.2 million per year, for 4 years (BRC) Up to $200,000 for one year, and $400,000 per year, for 4 years (CC)	Estimated post date: 7/7/23 Estimated proposal date: 10/26/23
		MEASUREMENT SCIENCE (1)		
53.	Measurement Science and Engineering (MSE) Research Grant Programs (DoC/NIST) 2023-NIST-MSE-01	NIST's mission is to drive innovation and industrial competitiveness through measurement science and standards by cultivating a culture of belonging that integrates diversity, equity, inclusion, and accessibility in all ways of working. Grant programs support activities in fields such as : bioscience, chemistry, dimensional metrology, electronics, engineering, infrastructure, information technology, manufacturing, manufacturing metrology, materials science and engineering, nanotechnology, neutron research, optics, and physics. https://www.grants.gov/web/grants/view-opportunity.html?oppId=347512	Dependent upon proposal and award mechanism	Proposals accepted through 4/14/25
		MEDICAL COUNTERMEASURES (1)		
54.	Sex Differences in Radiation Research: Models, Underlying Pathways, Biomarkers of Injury, and Medical Countermeasure Responses (U01 Clinical Trial Not Allowed) (NIH/NIAID/ORWH) RFA-AI-23-024	This NOFO aims to enable early-stage research to better understand the underlying causes of radiation-associated sex differences to advance radiation preclinical animal models, improve Medical Countermeasures (MCM) development, increase the safety and efficacy of MCMs, and advance biomarker science to assess radiation injuries. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-024.html	Up to $350,000 per year, for up to 3 years	Letter of intent: 8/6/23 Proposal: 9/6/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH (3)		
55.	Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed) (NIH/NIMH) PAR-23-168	This NOFO supports the development and validation of screening assays for the discovery of validated hits that can be used in future drug discovery/development efforts for identifying potential drug candidates for the treatment of mental illness. Stages of discovery research covered by this NOFO include 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); and 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set. https://grants.nih.gov/grants/guide/pa-files/PAR-23-168.html	Dependent upon proposal, for up to 5 years	Proposal: 6/5/23
56.	Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH) (U01 CT Optional)/(U24 CT Not Allowed) (NIH/NIMH) RFA-MH-23-105 (U01) RFA-MH-23-106 (U24)	These NOFOs are intended to stimulate and support research that will use behavioral measures and computational methods to define novel clinical signatures that can be used for individual-level prediction and clinical decision making in mental disorders, as well as for a Data Coordinating Center (DCC) that will support the research projects. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-105.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-106.html (U24)	Up to $2.5 million per year, for up to 5 years (U01) Up to $1 million per year, for up to 5 years (U24)	Letter of intent: 5/15/23 Proposal: 6/14/23
		MILITARY BURN (2)		
57.	FY23 Military Burn Research Program (MBRP) (DoD/CDMRP) HT9425-23-MBRP-CTRA HT9425-23-MBRP-TTDA	Applications submitted to the FY23 MBRP must address one or more of the following Focus Areas: Atypical Burns; Burn Injury During Mass Casualty; Burn injury-related complications. Two awards are offered: Clinical Translational Research Award and Technology/Therapeutic Development Award. https://cdmrp.health.mil/funding/mbrp	Up to $2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 5/31/23 Proposal: 9/4/23
		MULTIPLE SCLEROSIS (4)		
58.	FY23 Multiple Sclerosis Research Program (DoD/CDMRP) HT9425-23-MSRP-CTA HT9425-23-MSRP-EHDA HT9425-23-MSRP-EIRA HT9425-23-MSRP-IIRA	The MSRP supports innovative and impactful research that addresses fundamental issues and gaps in MS. Four awards are offered: Clinical Trial, Early Investigator Research, Exploration - Hypothesis Development, and Investigator-Initiated Research. https://cdmrp.health.mil/funding/msrp	Up to $4.5 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 6/8/23 Proposal: 10/6/23 (CTA/EHDA/IIRA) Pre-Application: 7/24/23 Proposal: 10/6/23 (EIRA)

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MUSCULOSKELETAL HEALTH (2)		
59.	NOSI: Supporting Exploratory/Developmental Research Focused on NIAMS Core Mission Areas (NIH/NIAMS) NOT-AR-23-006	Awards will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community. https://grants.nih.gov/grants/guide/notice-files/NOT-AR-23-006.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/27
		NEUROFIBROMATOSIS (8)		
60.	Pre-Announcement: FY23 Neurofibromatosis Research Program (DoD/CDMRP)	The FY23 NFRP anticipates eight awards: Research Academy-Leadership Award, Research Academy-Scholar Award, Clinical Trial Award, Early Investigator Research Award, Exploration-Hypothesis Development Award, Investigator-Initiated Research Award, New Investigator Award, and Synergistic Idea Award. All applications must address one or more Area of Emphasis. https://cdmrp.health.mil/pubs/press/2023/23nfrppreann	Up to $2 million, for up to 3 years Dependent upon award mechanism	TBD
		ORTHOTICS AND PROSTHETICS OUTCOMES RESEARCH PROGRAM (2)		
61.	FY23 Orthotics and Prosthetics Outcomes Research Program (DoD/CDMRP) HT9425-23-OPORP-CRA HT9425-23-OPORP-CTA	Applications submitted to the FY23 OPORP must address one or more of the following Strategic Goals: Optimize patient-specific technology prescription; Optimize patient-specific rehabilitation regimens; Support standardized assessment of patient outcomes related to prosthetics and orthotics. Two awards are anticipated: Clinical Research and Clinical Trial. https://cdmrp.health.mil/funding/oporp	Up to $4 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 6/27/23 Proposal: 7/12/23
		PARKINSON'S DISEASE (3)		
62.	FY23 Parkinson's Research Program's (PRP) (DoD/CDMRP) HT9425-23-PRP-EIRA HT9425-23-PRP-IIRA HT9425-23-PRP-SIA	Applications submitted to the three FY23 PRP awards must address one or more of the following Focus Areas: Biological mechanisms or biomarkers, including biologically informed clinical evaluations, of non-motor symptoms that could lead to the development of treatments for PD; Biological mechanisms or biomarkers associated with non-pharmacological interventions for PD. https://cdmrp.health.mil/funding/prp	Up to $3 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 7/27/23 Proposal: 8/17/23
		PATIENT-CENTERED RESEARCH (6)		
63.	Broad Pragmatic Studies Funding Announcement -- 2023 Standing PFA (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research projects. All applications must align the proposed research with at least one of the National Priorities for Health. Applicants have the option to choose up to three of eight topic themes. https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-funding-announcement-2023-standing-pfa-cycle-2	Up to $10 million, for up to 5 years Dependent upon award mechanism	Letter of intent: 5/31/23 Proposal: 8/29/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
64.	Phased Large Awards for Comparative Effectiveness Research -- Cycle 2 2023 (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-placer-cycle-2-2023	Up to $22 million, for up to 6.5 years	Letter of intent: 5/31/23 Proposal: 8/29/23
65.	Improving Methods for Conducting Patient-Centered Outcomes Research -- 2023 Standing PFA (PCORI)	For this PFA, PCORI has identified these programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-outcomes-research-2023-standing-pfa-cycle-2	Up to $750,000, for up to 3 years	Letter of intent: 5/31/23 Proposal: 8/29/23
66.	Implementation of Effective Shared Decision Making Approaches in Practice Settings -- Cycle 2 2023 (PCORI)	This initiative will support projects that propose active, multi-component approaches to implementing effective shared decision making strategies that address existing barriers and obstacles to uptake and maintenance. The SDM strategy must have demonstrated effectiveness on patient, caregiver, or healthcare provider decision making using widely accepted metrics; the corresponding implementation approach must have potential for use and scalability beyond the targeted implementation setting. https://www.pcori.org/funding-opportunities/announcement/implementation-effective-shared-decision-making-approaches-practice-settings-pfa-cycle-2-2023	Up to $2.5 million, for up to 3 years	Letter of intent: 5/31/23 Proposal: 8/29/23
67.	Open Competition PFA: Implementation of Findings from PCORI's Major Research Investments -- Cycle 2 2023 (PCORI)	For the Cycle 2 2023 PFA, PCORI has identified the following four areas of eligible evidence: Obesity Treatment in Primary Care Settings; Nonsurgical treatment options to improve or eliminate symptoms for women with UI; Therapy and medicines to reduce or stop symptoms for people with PTSD; Narrow-spectrum versus broad-spectrum antibiotics to treat children's ARTIs. https://www.pcori.org/funding-opportunities/announcement/open-competition-pfa-implementation-findings-pcoris-research-investments-cycle-2-2023	Up to $2.5 million, for up to 3 years	Letter of intent: 5/31/23 Proposal: 8/29/23
68.	Advancing the Science of Engagement PCORI Funding Announcement -- Cycle 2 2023 (PCORI)	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes; Techniques that lead to effective engagement; How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity; How engagement supports successful research. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-pcori-funding-announcement-cycle-2-2023	Up to $1.5 million, for up to 3 years	Letter of intent: 5/31/23 Proposal: 8/29/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PEER REVIEWED ORTHOPAEDIC RESEARCH PROGRAM (3)		
69.	FY23 Peer Reviewed Orthopaedic Research Program (PRORP) (DoD/CDMRP) HT9425-23-PRORP-ARA HT9425-23-PRORP-CTA HT9425-23-PRORP-CTRA	Applications submitted to the FY23 PRORP must address one or more of the Focus Areas listed on the program page. There are three award mechanisms: Applied Research, Clinical Trial, Clinical Translational Research. https://cdmrp.health.mil/funding/prorp	Up to $3 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 6/15/23 Proposal: 9/13/23
		RARE DISEASES (3)		
70.	Pre-Announcement: Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (NIH/NCATS) NOT-TR-23-015	This NOFO will solicit applications for research to advance the diagnosis, management, and treatment of rare diseases. Each Rare Diseases Clinical Research Consortium (RDCRC) will promote highly collaborative, multi-site, patient-centric, translational, and clinical research. https://grants.nih.gov/grants/guide/notice-files/NOT-TR-23-015.html	Up to $1 million per year, for up to 5 years	Estimated post date: 1/24/24 Estimated proposal date: 6/14/24
71.	Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21/R03 Clinical Trial Not Allowed) (NIH/NCATS/NICHD) PAR-23-159 (R21) PAR-23-160 (R03)	These NOFOs invite researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics toward clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials. https://grants.nih.gov/grants/guide/pa-files/PAR-23-159.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-23-160.html (R03)	Up to $275,000, for up to 2 years (R21) Up to $100,000, for up to 2 years (R03)	Letter of intent: 9/17/23 Proposal: 10/17/23
		RECONSTRUCTIVE TRANSPLANT (3)		
72.	Pre-Announcement: FY23 Reconstructive Transplant Research Program (RTRP) (DoD/CDMRP)	Applications to the three anticipated FY23 RTRP award mechanisms must address at least one of the Focus Areas specific to each award. The awards are: Idea Discovery Award; Investigator-Initiated Research Award Advanced Technology Development Award. https://cdmrp.health.mil/pubs/press/2023/23rtrppreann	Up to $1.5 million, for up to 3 years Dependent upon award mechanism	TBD

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		REGENERATIVE MEDICINE (2)		
73.	Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44/UT1/UT2) Clinical Trial Not Allowed (NIH/NCATS) PAR-23-267 (U43/44) PAR-23-268 (UT1/UT2)	These NOFOs provide SBIR/STTR support for the development of novel extracellular vesicle-based therapeutic platforms for use in regenerative medicine. Both native and engineered EVs have demonstrated the ability for specific and targeted tissue and organ repair, which can be harnessed for applications such as extracellular vesicle-based therapeutics. The main objective for these funding opportunities is to support platform-oriented technology development associated with the production, manufacturing, and use, of extracellular vesicles as therapeutics in regenerative medicine. https://grants.nih.gov/grants/guide/pa-files/PAR-23-267.html (U43/44) https://grants.nih.gov/grants/guide/pa-files/PAR-23-268.html (UT1/UT2)	Up to $295,924, for up to 6 months (Phase I) Up to $1,972,828, for up to 2 years (Phase II) Waiver topics: Up to $325,000 (Phase I) and up to $2 million (Phase II)	Proposal: 6/6/23
		REPRODUCTIVE HEALTH (2)		
74.	Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) (NIH) PAR-23-180	This NOFO supports the continued development of new and innovative on-demand, event-driven, and long-acting multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and pregnancy; sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs in cis and trans males and females of all ages. https://grants.nih.gov/grants/guide/pa-files/PAR-23-180.html	Dependent upon proposal, for up to 5 years	Proposal: 12/7/23
75.	Biological Testing Facility (X01 Clinical Trial Not Allowed) (NIH/NICHD) PAR-23-192	This NOFO provides investigators with a mechanism to request services from this facility that would advance their contraceptive development program. https://grants.nih.gov/grants/guide/pa-files/PAR-23-192.html	N/A	Proposal: 5/30/23
		RESEARCH RESOURCES (1)		
76.	BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed) (NIH) RFA-NS-23-026	This NOFO supports efforts to disseminate resources for integration into neuroscience research practice. Activities must include dissemination of an existing resource, and may include one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and/or specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-026.html	Dependent upon proposal, for up to 5 years	Letter of intent: 5/14/23 Proposal: 6/14/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT (3)		
77.	MTEC Commercialization Grants (MTEC) MTEC-E23-08-Commercialization	This RPP will provide non-dilutive MTEC awards that fund M-Corps partner engagement for the purpose of providing members professional services that advance commercialization readiness. The intent of this program is to help MTEC members advance their commercialization readiness of technologies with relevance to the military and the MTEC mission. https://mtec-sc.org/wp-content/uploads/2023/05/MTEC-E23-08-Commercialization-RPP.pdf	Up to $50,000, for up to 1 year	Proposal: 6/19/23
78.	Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed) (NIH) RFA-CA-23-035	This NOSI supports early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-035.html	Up to $295,924 (Phase I) Up to $1,972,928 (Phase II) Waiver topics may exceed these amounts	Letter of intent: 7/21/23 Proposal: 8/21/23
79.	Joint DoD SBIR 23.2 / STTR 23.B (DoD) SBIR 23.2 / STTR 23.B	The objectives of the DoD SBIR Program include stimulating technological innovation, strengthening the role of small business in meeting DoD research and development needs, fostering and encouraging participation by minority and disadvantaged persons in technological innovation, and increasing the commercial application of DoD-supported research or research and development results. Current topics include Portable, Real-Time DNA & RNA Sequencing; Computational Modeling of Human Blast Injuries; and Medical Simulations for Extreme Cold Weather Environments. https://www.defensesbirsttr.mil/SBIR-STTR/Opportunities/	Dependent upon agency and phase	Proposal: 6/14/23
		SUBSTANCE USE DISORDER (12)		
80.	NOSI: Assembling the Addiction Organelle Interactome (NIH/NIDA) NOT-DA-24-007	This NOSI encourages innovative studies on the role of organelle interactions and communications, and how organelle dynamics affect cellular homeostasis in the context of addiction. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-007.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/26
81.	Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (R34 CT Not Allowed) (NIH/NIDA) RFA-DA-24-019	This NOFO seeks applications proposing a set of planning activities that will lay the groundwork for scientific projects aimed at using animal models and longitudinal research designs to elucidate mechanisms mediating the impact of the early-life social environment on neurobehavioral development and the risk for substance use disorders (SUD) and their comorbidities in adolescence and adulthood. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-019.html	Up to $450,000, for up to 2 years	Letter of intent: 10/10/23 Proposal: 11/9/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
82.	Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Clinical Trials Not Allowed/Basic Experimental Studies with Humans Required) (NIH/NIDA) RFA-DA-24-020 RFA-DA-24-021	These NOFOs support research project applications to expand our knowledge on the basic neurobiology of and basic science experimental studies involving humans to expand our knowledge of the interrelationships between sleep/circadian rhythms and substance use disorders (SUDs). These mechanistic studies will offer insights into the fundamental processes that link SUDs to disorders of sleep/circadian rhythms and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-020.html https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-021.html	Up to $300,000 per year, for up to 3 years	Letter of intent: 10/13/23 Proposal: 11/13/23
83.	Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional) (NIH/NIDA) RFA-DA-24-038	This NOFO encourages grant applications proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this NOFO may fall within two scientific areas, namely: (1) pharmacotherapeutics and (2) medical therapeutic and diagnostic devices. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-038.html	Up to $320,000, for up to 1 year (Phase I) Up to $2.5 million, for up to for 3 years (Phase II)	Letter of intent: 7/15/23 Proposal: 8/15/23
84.	Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 CT Not Allowed) (NIH) RFA-TR-23-010	This NOFO supports early-stage research projects focusing on the identification of new druggable targets for pain, opioid use disorder and/or overdose within the understudied druggable proteome. https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-010.html	Up to $275,000, for up to 2 years	Proposal: 5/22/23
85.	Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed) (NIH) RFA-TR-23-011	This Award supports a postdoctoral or newly independent Early Stage Investigator of exceptional creativity who proposes novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research related to pain, opioid use disorder (OUD), and/or overdose (OD). https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-011.html	Up to $500,000 per year, for up to 3 years	Proposal: 5/22/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SYNTHETIC BIOLOGY (17)		
86.	NOSI: Synthetic Biology for Biomedical Applications (NIH) NOT-EB-23-002	The overarching goals of this NOSI are to: Develop tools and technologies to control and reprogram biological systems; Apply synthetic biology approaches for the development of biomedical technologies; Increase the fundamental understanding of synthetic biology concepts as they relate to human health; and Gain fundamental biological knowledge through the application of synthetic biology approaches. https://grants.nih.gov/grants/guide/notice-files/NOT-EB-23-002.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/17/26
		TRAUMATIC BRAIN INJURY (5)		
87.	FY23 Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) (DoD/CDMRP) HT9425-23-S-TBIPH1 HT9425-23-S-TBIPH2 HT9425-23-TBIPHRP-HSRA HT9425-23-TBIPHRP-IIRA HT9425-23-TBIPHRP-TRA	The FY23 TBIPHRP includes five awards: Clinical Trial Award, Focused Program Award, Investigator-Initiated Research Award, Translational Research Award, and Health Services Research Award. Applications submitted to the FY23 TBIPHRP must address one or more of the following Focus Areas, not all of which will be applicable to every award mechanism: Understand; Prevent and Assess; Treat. https://cdmrp.health.mil/funding/tbiphrp	Up to $5 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 6/8/23 Proposal: 7/6/23 (HSRA/IIRA/ TRA) Pre-Application: 6/15/23 Proposal: 9/28/23 (CTA/FPA)

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (1)		
88.	Open-Office Broad Agency Announcement (BAA) 75N99223S0001	Awardees will develop groundbreaking new ways to tackle health-related challenges through high-potential, high-impact biomedical and health research. ARPA-H has identified four initial focus areas that are a priority for investment: (1) Health Science Futures; (2) Scalable Solutions; (3) Proactive Health; (4) Resilient Systems. https://sam.gov/opp/caf109b75a0449418ead3630cef1915e/view	Dependent upon proposal and award mechanism	Abstract: 3/14/24
		AIR FORCE (3)		
89.	Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332	Up to $49 million, per award	White papers accepted on rolling basis until 4/30/26
90.	Research Interests of the Air Force Office of Scientific Research FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). https://www.grants.gov/web/grants/view-opportunity.html?oppId=345653	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE		
91.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/web/grants/view-opportunity.html?oppId=330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		ARMY (8)		
92.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/66870bda25274773b3e5fa7cfd3c0e11/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
93.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational Medicine; Medical Biological Defense; and Medical Chemical Defense. https://www.grants.gov/web/grants/view-opportunity.html?oppId=343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
94.	USSOCOM BAA for Extramural Biomedical Research and Development W81XWH-18-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries, prolonged field care, human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/web/grants/view-opportunity.html?oppId=307754	Dependent upon proposal	Proposals accepted through 7/31/23 Submission of a pre-proposal is required
95.	Army Research Office Broad Agency Announcement for Fundamental Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here: https://www.arl.army.mil/opportunities/arl-baa/ https://sam.gov/opp/72a662246119420d9215e60722caaac5/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
96.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/e8d78dcbe9e846f2af5fd1bfd04dc27c/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
97.	Army Applications Lab BAA for Disruptive Applications W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
98.	Army Research Office Broad Agency Announcement Staff Research Program W911NF20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences. https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf	Dependent upon proposal	Proposals accepted on a rolling basis until 2/19/25
99.	Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		BARDA (2)		
100.	BARDA Broad Agency Announcement BARDABAA	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antibacterials; Radiological, Nuclear & Chemical Threat MCMs; Burn Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; Next-generation COVID-19 Vaccines. https://sam.gov/opp/6f989eb9c421422788a4c3a9133917f0/view	Dependent upon proposal	White papers: 9/25/23; some AOIs due earlier
101.	BARDA DRIVe EZ-BAA EZBAA - 22-100-SOL-00003	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #15: ReDIRECT; AOI #17: Digital MCMs; AOI #18: Host-Directed Therapeutics; AOI #20: DRIVe Forward; AOI #22: ReBoot; AOI #23: Host-Based Diagnostics https://sam.gov/opp/2bf5a8c79c6046b99085d7eea9565e8a/view	Up to $750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DARPA (3)		
102.	Biological Technologies BAA HR001122S0034	BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, and deep exploration of changing ecologies and environments for improving U.S. capabilities and resilience. BTO is interested in submissions related to the following topic areas: Human Performance, Materials, Sensors, Processing, Biosecurity, Biomedical, and Biodefense https://sam.gov/opp/4b5b1e510470403cb744b75bfd0cb681/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 6/22/23
103.	Redefining Possible - 2022 HR001122S0040	The Tactical Technology Office (TTO) of DARPA is soliciting executive summaries, proposal abstracts, and proposals for applied research, advanced technology development, platform demonstrations, or systems studies that aim to redefine the future of warfighting across four domains: Air, Ground, Maritime, and Space. https://sam.gov/opp/a517e20d661b431aa933e55263a2bc42/view	Up to $1 million, for up to 18 months	Proposals accepted on a rolling basis until 6/21/23
104.	Defense Sciences Office, Office-wide HR001122S0041	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Global Change. https://sam.gov/opp/d99f59e0d48245e688b92af595380c79/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/14/23
		DEFENSE THREAT REDUCTION AGENCY (2)		
105.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view	Up to $1 million per year, for up to 5 years	White papers accepted through 9/2024
106.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/e23f86536f7840eaa868f3526a86a6ae/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEPARTMENT OF ENERGY (1)		
107.	FY2023 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0002844	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/web/grants/view-opportunity.html?oppId=343866	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/23
		NATIONAL SCIENCE FOUNDATION (1)		
108.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 23-515	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit.The NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. Click for project pitch details and for the full list of topics. https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm	Up to $275,000 for up to 1 year	Project pitches accepted on a rolling basis. Submission window for invited proposals: 3/2/23 to 7/5/23
		NAVY (3)		
109.	FY23 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943023S2501	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/14178e9157ad40b387ddb443071b0969/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/11/24
110.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N00014-23-S-B001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.nre.navy.mil/work-with-us/funding-opportunities/fy23-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/23
111.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-23-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/58eeca6ef84a4d25b41b0edaca42447a/view	Dependent upon proposal and award mechanism	White papers accepted through 9/30/23